380 related articles for article (PubMed ID: 28985505)
1. Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.
Jost M; Chen Y; Gilbert LA; Horlbeck MA; Krenning L; Menchon G; Rai A; Cho MY; Stern JJ; Prota AE; Kampmann M; Akhmanova A; Steinmetz MO; Tanenbaum ME; Weissman JS
Mol Cell; 2017 Oct; 68(1):210-223.e6. PubMed ID: 28985505
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent.
Jost M; Chen Y; Gilbert LA; Horlbeck MA; Krenning L; Menchon G; Rai A; Cho MY; Stern JJ; Prota AE; Kampmann M; Akhmanova A; Steinmetz MO; Tanenbaum ME; Weissman JS
Mol Cell; 2020 Jul; 79(1):191-198.e3. PubMed ID: 32619469
[TBL] [Abstract][Full Text] [Related]
3. A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent.
Baker SJ; Cosenza SC; Athuluri-Divakar S; Reddy MVR; Vasquez-Del Carpio R; Jain R; Aggarwal AK; Reddy EP
Mol Cell; 2020 Jul; 79(1):180-190.e4. PubMed ID: 32619468
[TBL] [Abstract][Full Text] [Related]
4. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
5. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
6. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.
Matthew S; Chen QY; Ratnayake R; Fermaintt CS; Lucena-Agell D; Bonato F; Prota AE; Lim ST; Wang X; Díaz JF; Risinger AL; Paul VJ; Oliva MÁ; Luesch H
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619102
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel microtubule inhibitors effective in fission yeast and human cells and their effects on breast cancer cell lines.
Morishita J; Nurse P
Open Biol; 2021 Sep; 11(9):210161. PubMed ID: 34493069
[TBL] [Abstract][Full Text] [Related]
8. Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na.
Mäki-Jouppila JH; Laine LJ; Rehnberg J; Narvi E; Tiikkainen P; Hukasova E; Halonen P; Lindqvist A; Kallio L; Poso A; Kallio MJ
Mol Cancer Ther; 2014 May; 13(5):1054-66. PubMed ID: 24748653
[TBL] [Abstract][Full Text] [Related]
9. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
10. Cellular effects of curcumin on Plasmodium falciparum include disruption of microtubules.
Chakrabarti R; Rawat PS; Cooke BM; Coppel RL; Patankar S
PLoS One; 2013; 8(3):e57302. PubMed ID: 23505424
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent microtubule-destabilizing agents targeting for colchicine site by virtual screening, biological evaluation, and molecular dynamics simulation.
Zhang H; Luo QQ; Hu ML; Wang N; Qi HZ; Zhang HR; Ding L
Eur J Pharm Sci; 2023 Jan; 180():106340. PubMed ID: 36435355
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.
Sun K; Sun Z; Zhao F; Shan G; Meng Q
Future Med Chem; 2021 May; 13(9):839-858. PubMed ID: 33821673
[TBL] [Abstract][Full Text] [Related]
13. Toward Discovery of Novel Microtubule Targeting Agents: A SNAP-tag-Based High-Content Screening Assay for the Analysis of Microtubule Dynamics and Cell Cycle Progression.
Berges N; Arens K; Kreusch V; Fischer R; Di Fiore S
SLAS Discov; 2017 Apr; 22(4):387-398. PubMed ID: 28328318
[TBL] [Abstract][Full Text] [Related]
14. A Multipronged Approach Establishes Covalent Modification of β-Tubulin as the Mode of Action of Benzamide Anti-cancer Toxins.
Povedano JM; Rallabandi R; Bai X; Ye X; Liou J; Chen H; Kim J; Xie Y; Posner B; Rice L; De Brabander JK; McFadden DG
J Med Chem; 2020 Nov; 63(22):14054-14066. PubMed ID: 33180487
[TBL] [Abstract][Full Text] [Related]
15. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
16. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
17. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.
Duan Y; Liu W; Tian L; Mao Y; Song C
Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108
[TBL] [Abstract][Full Text] [Related]
18. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties.
Cosentino L; Redondo-Horcajo M; Zhao Y; Santos AR; Chowdury KF; Vinader V; Abdallah QM; Abdel-Rahman H; Fournier-Dit-Chabert J; Shnyder SD; Loadman PM; Fang WS; Díaz JF; Barasoain I; Burns PA; Pors K
J Med Chem; 2012 Dec; 55(24):11062-6. PubMed ID: 23176628
[TBL] [Abstract][Full Text] [Related]
20. Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance.
Cheng B; Zhu G; Meng L; Wu G; Chen Q; Ma S
Eur J Med Chem; 2022 Jan; 228():113930. PubMed ID: 34794817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
